-Reuters Citing Filing
Related Posts
Immatics Reports Interim Clinical Data Update On ACTengine IMA203 TCR-T Monotherapy Targeting PRAME
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expression
Update covers data from
RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $88
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and lowers the price target from $92 to $88.
